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type 2 diabetic patients above 18 years who underwent QST using computer-
driven Medoc TSA II NeuroSensoryAnalyzer system from a period of October 
2011 to May 2012. The results of QST were compared to those of monofilament 
test. RESULTS: Ninety-nine patients (73 males, 26 females) with an average age 
51.49±11.07 years (range: 18-76 years) were recruited in the study. The sensitivity 
and specificity of QST to determine Warm Sensation Threshold, Cold Sensation 
Threshold, Heat Pain Threshold and Cold Pain Threshold in comparison to 
monofilament test was found to be maximum in case of Warm Sensation 
Threshold (86% and 94.5%, respectively). Cold Sensation Threshold was found to 
be inversely proportional to HbA1c (correlation=-0.0909) as well as age 
(correlation=-0.4395). It was also seen that Cold PainThreshold was inversely 
proportional to age (correlation=-0.2143) and Heat Pain Threshold was directly 
proportional to age (correlation=0.2698). CONCLUSIONS: Taking into 
consideration, the high sensitivity and specificity of quantitative sensory testing 
in case of Warm Sensation Threshold and limitations of our study, we conclude 
that Quantitative Sensory Testing can be of use in detecting diabetic peripheral 
neuropathy if used in proper way.  
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OBJECTIVES: High rates of undiagnosed chronic kidney disease (CKD) in type-2 
diabetics (T2DM) indicate that it may not take priority relative to other 
comorbidities. This study examined the prevalence and costs of stage 3-5 CKD in 
relation to other comorbidities within an insured patient population. METHODS: 
Medical and pharmacy claims and laboratory results from a US commercially-
insured population were used to identify patients aged 18-64 with T2DM from 
2006-2010 (the first observed diagnosis as the index date), continuous follow-up 
for 12 months following the index date, and a serum creatinine finding. 
Comorbid hypertension, dyslipidemia, heart diseases/stroke, eye problems, and 
neuropathy were identified during the post-index period based on diagnosis 
codes. Stage 3-5 CKD was identified by medical claims or laboratory findings 
with glomerular filtration rate <60 mL/min/1.73m2. Annual total health care costs 
were reported at follow-up for the selected comorbidities. Generalized linear 
regression models were used to estimate the incremental costs of a given 
comorbidity. RESULTS: The final study sample included 101,964 T2DM patients 
(47.7% hypertension; 53.5% dyslipidemia; 9.7% heart diseases/stroke; 11.6% eye 
problems; 7.0% neuropathy; 9.2% stage 3-5 CKD). The direct annual total mean 
health care costs were $13,158 for all T2DM patients and were as follows for the 
selected comorbidities: hypertension: $16,676; dyslipidemia: $13,537; heart 
diseases and stroke: $39,987; eye problems: $16,017; neuropathy: $24,563; and 
stage 3-5 CKD: $28,325. After adjustment, the incremental costs of these selected 
comorbidities were $2,650, -$545, $17,752, $587, $6,043, and $7,792, respectively 
(all p<0.01). CONCLUSIONS: Among the commercially insured diabetics, the 
prevalence of CKD is similar to heart diseases/stroke, eye problems and 
neuropathy and had the second highest annual health care costs after heart 
diseases/stroke. The burden associated with moderate to severe CKD indicates 
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OBJECTIVES: Self-Measurement of Blood Glucose (SMBG) is an important part  
of good diabetes management. Guidelines suggest frequent SMBG testing (the 
number depending on type of diabetes treatment), but there are also limitations 
in some countries on the maximum number of reimbursed strips per month. 
Each SMBG strip costs approximately 0.5€. Limited information on frequency  
of SMBG exists, although it accounts for a considerable proportion of diabetes 
management costs. METHODS: Data were drawn from the 2012 Adelphi Diabetes 
Disease Specific Programme, a cross-sectional survey involving 374 primary  
care physicians and 256 specialists across Europe. Doctors completed patient 
record forms for 7528 consulting patients, 4839 of whom independently 
completed a self-completion questionnaire. SMBG testing frequency was 
analysed separately for type-1 (T1) and type-2 (T2) diabetics and type of 
treatment (non-insulins, basal-only treatment (BOT), basal-bolus (BB) and other 
insulins). RESULTS: Proportion of patient-reported SMBG, T1 93.7%, T2 BOT 
81.0%,T2 BB 88.7%. Physicians reported similar proportions of patients measuring 
their own glucose (T1 94.8%, T2 BOT 79.8% and T2 BB 90.3%). Physician 
recommended SMBG testing between (mean) 31.5 (T2 non-insulins) and 92.4 (T1) 
tests per month with 48.7 for T2 BOT, 81.0 for T2 BB users. The actual mean 
number of patient-reported SMBG tests per month is between 28.8 (T2 non-
insulins) and 94.1 (T1), with 43.4 for T2 BOT, 83.5 for T2 BB.There is thus high 
consistency between patient and physician responses on proportion of patients 
performing SMBG and frequency of testing per month. CONCLUSIONS: Diabetes 
patients appear to accurately follow the SMBG recommendation from their 
physician. Insulin-treated diabetes is associated with frequent SMBG testing, and 
testing frequency increases with number of daily insulin injections. Treatment 
and technologies that can reduce the need for SMBG without compromising 
overall diabetes management could help to reduce overall diabetes management 
costs.  
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OBJECTIVES: To assess the effect of statins on change in renal functions in 
patients with diabetic kidney disease (DKD). METHODS: Medline, Cochrane 
Central Register of Controlled Trials, SCOPUS, PsycINFO, and Web of Science 
databases were searched using the search terms that included Medical Subject 
Headings (MeSH) terms as well as text words. Randomized controlled (either 
parallel or crossover design) trials (RCTs), or quasi-randomized controlled trials 
of statins compared with placebo, other statins, or other drugs conducted in 
patients with either Type 1 or Type 2 DKD were included. We excluded studies in 
patients with kidney injury due to disease other than diabetes mellitus (such as 
gestational diabetes), patients on dialysis and/or with end-stage renal disease, 
and non-English articles. The primary endpoints were the rate of change in 
estimated Glomerular Filtration Rate (GFR) (ml/min) and the change in urine 
albumin excretion rate (AER) from baseline to follow-up. The quality of the 
studies was assessed using risk of bias assessment tool. RESULTS: The search 
yielded 738 studies of which 12 studies, with 3559 patients aged 18 years or older, 
were included. Statins comprised of atorvastatin (n=2), simvastatin (n=5), 
rosuvastatin (n=2), fluvastatin (n=1), lovastatin (n=1), and pravastatin and 
pitavastatin (n=1). The mean duration of follow-up was 15.75 months. Six of the 
studies were double-blinded. The studies were heterogeneous in design, 
treatment, dose and duration of follow-up. In six studies statins either 
significantly reduced albuminuria or prevented the rise of albuminuria. In five 
studies statin use retarded the deterioration of GFR. Thus, statins showed 
modest beneficial effect on renal functions in patients with DKD. CONCLUSIONS: 
Statins may delay the progression of kidney disease in diabetic patients. 
However, additional studies with larger sample size and longer duration of 
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OBJECTIVES: The likelihood of reaching A1C treatment targets using 
monotherapy with antihyperglycemic agents (AHAs) is low in patients (pts) with 
type 2 diabetes (T2DM) and moderately elevated A1C levels. AACE/ACE 
guidelines recommend initiating dual therapy (DT) with AHAs in untreated pts 
with an A1C 7.6 – 9.0%. This analysis was to estimate the proportion of 
treatment-naïve pts with T2DM and an A1C 7.6 – 9% who initiate AHA treatment 
with DT and associated pt-related factors. METHODS: Using GE EMR database, 
pts included had a T2DM diagnosis from 2003 to 2010, ≥1 A1C measurement 7.6 – 
9.0% (first instance = index date), continuous enrollment for ≥12 months before 
and ≥6 months after index date, and no AHA prescriptions in one year prior to 
index date. Pts receiving AHA prescriptions for DT within 30 days of index date 
were considered to have initiated DT at index date. Logistic regression identifies 
factors associated with initiating DT. RESULTS: Of the 30,501 selected pts, 8% 
initiated AHA DT and 36% initiated monotherapy within 30 days of the index 
date. After adjusting for baseline, pts with T2DM and an A1C 7.6 – 9.0% were 
more likely to initiate AHA DT if they had higher A1C (adjusted OR = 1.78 [95% CI: 
1.61, 1.97]). Pts were less likely to be prescribed AHA DT if they were older (per 5-
year OR = 0.95 [0.92, 0.97]), lived in regions outside of the South (ORs ranged from 
0.44 – 0.68 for different regions compared to South), or had chronic renal 
disease/renal failure (OR [95% CI] = 0.46 [0.28, 0.76]). CONCLUSIONS: In summary, 
in a cohort of untreated pts meeting AACE/ACE guideline recommendation for 
initiating DT, the proportion of pts initiating DT (8%) or any AHA regimen (44%) 
was low. More strenuous efforts are needed to address underutilization of AHAs 
and appropriate use of DT.  
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OBJECTIVES: We estimated economic burden associated with emergency 
department (ED) visits and outpatient/ambulatory visits for hypoglycemia for 
year 2005-2009. METHODS: We analyzed the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) and the National Ambulatory Medical Care 
Survey (NAMCS). The NHAMCS has ED and outpatient department (OPD) 
components. The unit cost can be estimated from the Medical Expenditure Panel 
Survey (MEPS) for patients with diabetes (n=1010 in 2005, 1115 in 2006, 1039 in 
2007, 1164 in 2008, 1276 in 2009). The annual costs were estimated by the 
multiplication of the MEPS unit costs and annual NHAMCS and NAMCS health 
care utilization associated with hypoglycemia. We did not estimate the annual 
hospitalization costs in NHAMCS OPD and the NAMCS due to no information on 
length of stay. All costs were adjusted to the U.S. 2009 dollars. RESULTS: The 
MEPS unit cost increased from $692 in 2005 to $932 in 2009, the annual 
expenditure of hypoglycemia ED visits fluctuated between $339 million in 2007 
and $400 million in 2006 due to the estimated total hypoglycemia visits declined 
over those 5 years. Hospital admissions from emergency department associated 
